Recent regulatory actions from the FDA, including new drug application (NDA) acceptances and labeling updates, introduce new clinical considerations for oncology nurses and advanced practice providers ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple myeloma treatment paradigm, the drug is still finding ways to consolidate its ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

Carol Meyers, 72, knew exactly how her daughter was feeling. Her daughter, Carley Yelyashov, 44, was in the hospital in June 2024 for a stem cell transplant, when healthy stem cells are infused into ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

In June 2025, we reported on a study that showed long-term survival with undetectable disease in heavily pretreated multiple myeloma. The results not only added fresh evidence of efficacy for CAR ...

Key abstracts on multiple myeloma from the 2025 American Society of Hematology Annual Meeting are reported by Dr Joseph Mikhael, chief medical officer of the International Myeloma Foundation. Dr ...

In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with ...

Please provide your email address to receive an email when new articles are posted on . Teclistamab plus daratumumab significantly improved PFS and OS for patients with relapsed, refractory multiple ...